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OBJECTIVEdTo evaluate if type 2 diabetes is an independent risk predictor for severe oste-
oarthritis (OA).
RESEARCH DESIGN AND METHODSdPopulation-based cohort study with an age-
and sex-stratified random sample of 927 men and women aged 40–80 years and followed over
20 years (1990–2010).
RESULTSdRates of arthroplasty (95% CI) were 17.7 (9.4–30.2) per 1,000 person-years in
patients with type 2 diabetes and 5.3 (4.1–6.6) per 1,000 person-years in those without (P ,
0.001). Type 2 diabetes emerged as an independent risk predictor for arthroplasty: hazard ratios
(95%CI), 3.8 (2.1–6.8) (P, 0.001) in an unadjusted analysis and 2.1 (1.1–3.8) (P = 0.023) after
adjustment for age, BMI, and other risk factors for OA. The probability of arthroplasty increased
with disease duration of type 2 diabetes and applied to men and women, as well as subgroups
according to age and BMI. Our findings were corroborated in cross-sectional evaluation by more
severe clinical symptoms of OA and structural joint changes in subjects with type 2 diabetes
compared with those without type 2 diabetes.
CONCLUSIONSdType 2 diabetes predicts the development of severe OA independent of
age and BMI. Our findings strengthen the concept of a strong metabolic component in the
pathogenesis of OA.
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O steoarthritis (OA) is among themost frequent chronic diseases inthe industrialized world, with esti-
mation for the lifetime prevalence ranging
from 30–50% (1,2). Moreover, OA is as-
sociated with a substantial disease burden
due to pain, functional decline and in-
creased mortality (2). In a proportion of
individuals, OA progresses toward joint
failure requiring total joint replacement
(arthroplasty). In the U.S., 200,000 hip
joints are replaced every year, and inter-
vention rates for hip and knee OA are
between 50 to 130 per 100,000 person-
years in most Western countries (3). Rel-
evancy of OA for public health will further
increase owing to the incremental ageing
and overnutrition (4). OA already con-
stitutes a major source of morbidity and is
considered as driving force of health costs
in aged populations next to cardiovascular
disease, type 2 diabetes, and dementia.
Despite the striking impact of OA, its
etiopathogenesis is still poorly defined,
with limited experimental insights into
disease mechanisms and the underlying
risk factors. It is well established, how-
ever, that OA shares similarities with type
2 diabetes, including its chronic nature,
high prevalence of end-organ failure,
and strong association with age and obe-
sity (5–7). Whether type 2 diabetes
represents a causal risk factor for OA re-
mains unclear to date (8). Metabolic fac-
tors are important for the development of
OA as suggested by several lines of evi-
dence: 1) The association between obesity
and OA extends beyond weight-bearing
joints, suggesting that this link is not
solely based on mechanical factors (9).
2) Metabolic syndrome is significantly
more common among subjects with
than without OA (10,11). In accordance,
fasting glucose levels are higher in OA pa-
tients than in non-OA controls (11,12). 3)
Finally, a small cross-sectional study from
the 1960s (13) showed higher prevalence
of radiographic OA in diabetic subjects
than in nondiabetic individuals and a later
evaluation on radiographic hip OA in pa-
tients receiving hip arthroplasty showed a
surplus of bilateral joint involvement in
diabetic patients (13,14).
In this study, we hypothesize that
type 2 diabetes indeed represents an in-
dependent risk factor for the develop-
ment of severe OA. We thus investigated
the risk for arthroplasty, as well as clinical
symptoms and imaging signs of OA in
diabetic and nondiabetic subjects in-




Characteristics of the Bruneck Study
The Bruneck cohort is a prospective
population-based study on the epidemi-
ology and pathogenesis of cardiovascular,
neurologic, and musculoskeletal diseases
(15–17), which has already been used to
define the impact of type 2 diabetes on
cardiovascular disease (18,19). This cohort
is characterized by unique homogenous
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access to one public health care system,
represented by the Bruneck Hospital,
which is the only health care provider in
the entire region. Thus, all medical records
of each individual were collected and com-
pletely accessible in the same place, mini-
mizing bias due to incomplete medical
information.
Patients
The study population was recruited in
1990 (baseline) as a random sample (n =
1,000), stratified according to sex and
age, of all inhabitants of Bruneck (125
women and 125 men in each of the fifth
to eighth decades of age). A total of 927
men and women were enrolled and fol-
lowed until 2010, with examinations con-
ducted every 5 years (1990, 1995, 2000,
2005, and 2010) and participation rates
.90%. Population mobility within the
Bruneck area was low at 0.2% per year
and migration to outside communities
was a rare event (n = 4 during the 20 years
of follow-up).We succeeded to trace all of
these few individuals, who participated in
the follow-up exam or provided access to
their medical records.
Data on type 2 diabetes and arthro-
plasty were available in all 927 subjects,
including 576 subjects who were alive in
2010 and 351 subjects who died during
the 20 years of follow-up. The study pro-
tocol of the Bruneck Study was reviewed
and approved by the ethics committees of
Bolzano and Verona, and all study subjects
gave their written informed consent.
Baseline and follow-up examinations
At baseline and each 5-year follow-up,
demographic and socioeconomic charac-
teristics, comorbidities, and medication
(including antidiabetic treatment, analge-
sic, and nonsteroidal anti-inflammatory
drugs) were recorded. Assessment of co-
morbidities included cardiovascular dis-
ease (angina, myocardial infarction, heart
failure, claudication, and stroke), cancer,
chronic obstructive pulmonary disease
(including asthma, bronchitis, and emphy-
sema), arterial hypertension, chronic in-
flammatory disease, and neuropsychiatric
disorders. Data were retrieved from 1) clin-
ical history taking and medical record re-
view; 2) complete physical and neurologic
examination; and 3) measures such as
blood pressure recording, electrocardio-
graphy, and carotid ultrasonography. Poly-
neuropathy was ascertained by a thorough
clinical examination conducted by an ex-
perienced senior neurologist and graded as
mild (sub- or preclinical disease), moderate
(manifest sensory and/ormotor deficits), or
severe (disabling disease with severe im-
pairment of gait).
Ascertainment of type 2 diabetes
Presence of type 2 diabetes was diagnosed
according to the classic American Diabe-
tes Association criteria (fasting glucose
$7 mmol/L [126 mg/dL] or a clinical di-
agnosis of type 2 diabetes with ongoing
antidiabetic treatment) (20). In a sensitiv-
ity analysis, the most recent diagnostic
criteria were applied (fasting glucose $7
mmol/L [126 mg/dL] or a clinical diagno-
sis of type 2 diabetes with ongoing anti-
diabetic treatment or HbA1c levels$6.5%
or 2-h glucose level $11.1 mmol/L [200
mg/dL] after a standard 75-g glucose
load) (21). The BMI was calculated as
weight divided by height squared
(kg/m2). Smoking status and alcohol con-
sumption were recorded as detailed pre-
viously (15–17). Physical activity was
recorded by composed score for work
(three categories) and sports/leisure activ-
ities (0,#2, and.2 h per week) (15–17).
Socioeconomic status was categorized
on a three-category scale (low, medium,
and high) based on information about oc-
cupational status and educational level of
the person with the highest income in the
household (15–17). Blood samples were
drawn after an overnight fast and absti-
nence from smoking. Total cholesterol,
HDL cholesterol, uric acid, creatinine,
ferritin, and high-sensitivity C-reactive
protein were all assessed by standard
methods (15–17). LDL cholesterol was
calculated with the Friedewald formula
except for patients with a triglyceride level
.400 mg/dL. Vascular cellular adhesion
molecule (VCAM)-1wasdetectedbyenzyme-
linked immunosorbent assay (17).
Longitudinal assessment of
arthroplasty between 1990 and 2010
Localization, date, and circumstances of
total hip and knee arthroplasty occurring
between 1990 and 2010 were carefully re-
corded using three sources of information:
subject self-report, medical records of the
BruneckHospital and general practitioners,
and a standardized evaluation of all ra-
diographs ever taken on study subjects.
Arthroplasty following bone fractures
(documented by radiographs) was not con-
sidered in the current analysis. All subjects
with arthroplasty had radiographically
documented OA of the hip or knee joint
in at least two sequential radiographs
(Kellgren-Lawrence score of at least one)
before surgery and met the criteria for the
diagnosis of OA (22,23). Two independent
readers (R.L. and C.P.) unaware of the sta-
tus of diabetes assessed the radiographs.
Cross-sectional clinical assessment
of OA in 2010
In the 2010 follow-up exam, a total of 576
individuals were still alive and had full
information on arthroplasty and of these,
488 participated in fourth follow-up. The
self-administered questionnaires of the
Knee Injury and Osteoarthritis Outcome
Score (KOOS) and the Western Ontario
and McMaster University Osteoarthritis
Index (WOMAC), both addressing the
severity of symptoms (pain, stiffness, and
joint function) associated with OA, were
filled out by 347 men and women who
did not differ from the overall group of
488 participants in any of the population
characteristics assessed.
Cross-sectional imaging assessment
of OA in 2010
In order to evaluate the severity of kneeOA,
bilateral ultrasound (US) examination of
the knee joints was performed by an in-
dependent experienced examiner blinded
to clinical symptoms and presence of lab-
oratory or radiographic abnormalities in
443 individuals (90.8%) (24–26). The US
exam was performed by a single reader
(C.P.) using an ESAOTE MyLab25 US
system (Esaote Biomedica, Genoa, Italy)
equipped with a broadband 4–13MHz lin-
ear transducer for US examination. Both
transverse and longitudinal scans of the
supra-and infrapatellar region and the lat-
eral and medial recesses were performed.
Presence of synovitis (i.e., hypoechoic sy-
novial hypertrophy and joint effusion ac-
cording to the Outcome Measures in
Rheumatology definition) in grayscale and
power Doppler signal in the synovial mem-
brane (settings: pulse repetition frequency
750 Hz, gain 40–50 dB) were recorded in
each compartment. Presence of grayscale
synovial hypertrophy and joint effusion as
well as Doppler signal was recorded ac-
cording to a semiquantitative scale (0 = nor-
mal; 1 =mild change; 2 =moderate change;
3 = severe change). The summed total score
of inflammatory-related abnormalities (ef-
fusion, synovial hypertrophy, and power
Doppler signal) was also calculated (range
from 0–9 in each joint).
Statistical analysis
Data were analyzed using the statistical
packages SPSS version 18.0 (SPSS) and
STATA version 10.1 (StataCorp). For com-
putation of intervention rates, person-years
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of follow-up for each participant were
accrued from the 1990 baseline until ar-
throplasty, age 90 years, death, or 1 Octo-
ber 2010, whichever came first. Cox
proportional hazard models were fitted to
assess the association between baseline
type 2 diabetes and arthroplasty due to
severe OA during follow-up. The propor-
tional hazard assumption was confirmed
for type 2 diabetes by testing the interaction
of type 2 diabetes with a function of
survival time (Cox model with time-
dependent covariates). When the exact
date of arthroplasty was not available, we
used the date of the first X ray showing the
implant as a surrogate. This may be viewed
as an adequate approximation in most
individuals and, if at all, errs on the con-
servative side. The base model was un-
adjusted, whereas multivariable models
were adjusted for established predictors of
severe OA [age, sex, prior arthroplasty,
BMI, and loge-transformed level of soluble
VCAM-1 (17); model 1] and, additionally,
for social class, smoking, alcohol consump-
tion, physical activity score, and levels of
uric acid, creatinine, LDL cholesterol, loge-
transformed high-sensitivity C-reactive
protein (hsCRP), and ferritin (model 2).
Differential effects of type 2 diabetes on
the probability of arthroplasty in subgroups
according to age, sex, and BMI were tested
by inclusion of appropriate interaction
terms. Sensitivity analyses with an update
of key variable (diabetes status and BMI)
were fitted using Cox regression analysis
with time-dependent covariates in order
to control for switches in diabetes status
and forweight gain during follow-up.Com-
parison of US measures and clinical score
levels between subjects with and without
type 2 diabetes (2010) was performed
with the t test and x2 test (for trend in
case of more than two categories) and,
in a multivariable setting, with uncondi-
tional logistic regression analysis and gen-
eral linear models. All reported P values
were two-sided.
RESULTS
Prospective analysis of arthroplasty
in subjects with and without type 2
diabetes in the Bruneck Study
(1990–2010)
At baseline, 69 of the 927 participants of
the Bruneck Study met the diagnostic
criteria for type 2 diabetes. MeanHbA1c at
baseline was 7.2%. Oral antidiabetic
drugs were used in 41 and insulin in 3
of the 69 participants. A total of 31 of
the 69 patients with diabetes (44.9%)
had clinical signs of a polyneuropathy at
baseline (mild, 20; moderate, 11; severe,
0), and this proportion increased to
55.1% during follow-up (mild, 22; mod-
erate, 16; severe, 0). No subjects had been
affected by type 1 diabetes. Baseline char-
acteristics of diabetic and nondiabetic
subjects are summarized in Table 1.
Between 1990 and 2010, 13 arthro-
plasties due to severe symptomatic hip/
knee OA were performed in diabetic sub-
jects corresponding to an intervention
rate (95% CI) of 17.7 (9.4–30.2) per
1,000 person-years. During the same pe-
riod, 73 interventions were done in the
nondiabetic group corresponding to an
intervention rate (95% CI) of 5.3 (4.1–
6.6) per 1,000 person-years. In unad-
justed Cox models, the hazard ratio
(HR) (95% CI) of joint failure for type 2
diabetes was 3.8 (2.1–6.8) (P , 0.001)
(Table 2). Remarkably, type 2 diabetes
remained a significant predictor of arthro-
plasty after controlling for a variety of
other putative risk factors for OA includ-
ing age and BMI (HR [95% CI], 2.1 [1.1–
3.8]; P = 0.023). To account for weight
gain during follow-up (e.g., related to in-
sulin treatment), BMI was updated every
5 years during follow-up from 1990–
2010 (Table 2). This sensitivity analysis
yielded similar risk estimates for type 2
diabetes (HR [95% CI], 2.2 [1.2–4.1];
P = 0.013). Several further sensitivity
analyses with an update of diabetes status
during follow-up or application of the
most recent American Diabetes associa-
tion definition of diabetes (21) yielded
very similar results (Table 2). Findings
were also consistent when additionally
adjusting the analysis for lifestyle factors
including smoking and physical activity
and serum parameters such as CRP (HR
[95%CI], 2.1 [1.1–4.0]; P = 0.026) (Table
2). Moreover, results were similar in men
and women and subgroups according age
and BMI (P values for interaction: 0.421,
0.844, and 0.192). Of note, severity of
OA, as assessed by the Kellgren-Lawrence
score (range 0–10 points) in the last ra-
diograph prior to arthroplasty, was simi-
lar in subjects with and without type 2
diabetes (mean 6 SD: 5.5 6 1.7 vs.
5.8 6 1.6 points, both values resembling
severe radiographic Kellgren-Lawrence
stage 3 OA; P = 0.84), as was the mean
age at surgery (74.1 vs. 72.6 years;P= 0.35).
In the cumulative hazard plot (Fig. 1),
the lines for diabetic and nondiabetic
subjects diverged over time, indicating
relevance of disease duration for the man-
ifestation of severe OA. Mean time be-
tween diagnosis of type 2 diabetes and
joint failure necessitating surgical inter-
vention was 10.7 years in our cohort. In
line, type 2 diabetes disease duration was
Table 1dBaseline demographic, lifestyle, and laboratory characteristics in subjects with
and without type 2 diabetes (n = 927)
Characteristic*
Type 2 diabetes
P value†No (n = 858) Yes (n = 69)
Age (years) 58.2 6 11.3 67.6 6 9.6 ,0.001
Male sex (%) 50.3 49.7 0.451
BMI (kg/m2) 24.8 6 3.7 27.0 6 3.9 ,0.001
Social status (%)
Low 61.4 75.4 0.923
Medium 21.7 7.2
High 16.93 17.4
sVCAM-1 (ng/mL) 609.2 (491.8–789.7) 736.9 (600.9–876.7) 0.036
Smoking (%) 24.7 18.8 0.636
Alcohol consumption (g/day) 30.8 6 40.6 36.56 6 49.0 0.385
Physical activity (score) 4.4 6 1.5 3.6 6 1.6 0.011
Uric acid (mmol/L) 315.2 6 83.3 368.8 6 113.0 0.005
Creatinine (mmol/L) 69.8 6 36.2 71.4 6 15.0 0.853
LDL cholesterol (mmol/L) 3.56 6 0.98 3.78 6 1.09 0.147
hsCRP (mg/L) 1.4 (0.8–5.7) 3.1 (1.4–8.0) 0.001
Ferritin (pmol/L) 318.8 6 340.6 613.4 6 783.5 ,0.001
sVCAM-1, soluble VCAM-1. *Values presented are means 6 SD, median (interquartile range), or percen-
tages. Factors to convert Système International units into conventional units are as follows: LDL cholesterol,
0.02586; and creatinine, 88.4. †P values for the variables age and sex are from unadjusted analyses. All other
P values are from logistic regression models adjusted for age and sex. For computation of P values, CRP
and sVCAM levels were loge-transformed because of a markedly skewed distribution.
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significantly higher in diabetic patients
with arthroplasty than in those without
arthroplasty (Fig. 1).
Subjects with impaired fasting glu-
cose at baseline (1990, n = 86) showed a
moderately elevated risk of arthroplasty
due to severe OA (unadjusted HR [95%
CI], 2.0 [1.1–3.7]; P = 0.030), which lost
significance in the multivariable model
(HR [95% CI], 1.6 [0.9–3.0]; P = 0.145).
Cross-sectional analysis of OA in
diabetic and nondiabetic subjects
in 2010
On a cross-section (2010), patients with
prevalent diabetes (n = 74) were more
likely to have received replacement of
knee and hip joint (implanted for allevia-
tion of OA symptoms) than nondiabetic
individuals (knee arthroplasty, interven-
tion proportion 10.8 vs. 3.3%, P = 0.006;
hip arthroplasty, intervention proportion
9.5 vs. 5.0%, P = 0.167). To further elab-
orate the association between type 2 di-
abetes and OA, a number of ancillary
cross-sectional analyses were performed.
Evaluation of the clinical symptoms of
OA by total WOMAC score, a validated
patient-related measure of signs and
symptoms of OA, showed significantly
more severe OA symptoms in subjects
with type 2 diabetes than in controls (Ta-
ble 3). Results were consistent in unad-
justed (P = 0.034) and fully adjusted
models (P = 0.030). Moreover, WOMAC
subscales for joint pain and function were
lower (i.e., more pathologic in type 2 di-
abetic patients than controls) (P values
from multivariable analyses 0.014 and
0.004; Table 3). Finally, results were rep-
licated when applying another validated
score for the quantification of clinical
disease activity in OA, the KOOS ques-
tionnaire (pain score, P value from multi-
variable analyses 0.001; Table 3).
We performed examinations of knee
joints by US in 443 individuals of the
Bruneck Study population in 2010
(90.8%), searching for signs of inflamma-
tion including synovitis and joint effu-
sion. Subjects without US data (n = 55)
were more likely to be female and diabetic
but otherwise similar to the entire popu-
lation. Bilateral joint effusion was found
in 51.1% of subjects with type 2 diabetes
but only in 30.9% of the subjects without
type 2 diabetes (Table 3). In accordance,
uni- and bilateral signs of synovitis in
the knee joints were significantly more
frequent in diabetic than nondiabetic sub-
jects (P value from multivariable analyses
0.004; Table 3). Data were consistent when
focusing on both synovitis and effusion in a
single model (P value from multivariable
analyses 0.003; Table 3). Finally, severity
of synovitis as quantified by the synovitis
score was more pronounced among pa-
tients with type 2 diabetes (Table 2).
CONCLUSIONSdTo our best knowl-
edge, this is the first time that it was
shown that diabetes can be considered as
an independent predictor of severe OA
necessitating joint arthroplasty. OA is a
major challenge to health in the industri-
alized world. 1) Its prevalence is high and
further increases due to ageing of the pop-
ulations. 2) Furthermore, its impact on
quality of life is substantial due to an im-
pairment of locomotor function and de-
crease in functional capacities. 3) Finally,
its conservative treatment options are lim-
ited, and surgical replacement of dam-
aged joints may be necessary in severe
cases. Therefore, definition of risk predic-
tors for OA is of key importance, particu-
larly if these risk factors can be modified
by either lifestyle changes or medications.
In this study, we show that long-standing
type 2 diabetes is independently associ-
ated with advanced OA of knee and hip
joints. This finding adds to the yet short
list of risk predictors for OA established
in prospective evaluations (5,6,17). After
controlling the analysis for age, BMI, and
other potential confounders, type 2 dia-
betes comprised a twofold risk of severe
OA necessitating arthroplasty.
The population-based design is a
strength of this study (27,28), as well as
its long-term and complete follow-up and
the use of joint failure necessitating ar-
throplasty as a hard end point. A further
strength of our study is that the link be-
tween type 2 diabetes and OA was consis-
tent when using three distinct approaches
of OA ascertainment as follows: 1) joint
failure as determined by arthroplasty; 2)
signs and symptoms of OA as quantified
by theWOMAC and KOOS scores; and 3)
severity of joint changes as determined by
musculoskeletal US.
Themoderate number of arthroplasties
(,100) can be considered as a limitation of
study. However, this is not surprising be-
cause arthroplasty accomplishes the most
Table 2dProspective association of type 2 diabetes with severe OA requiring joint
arthroplasty during 20 years of follow-up (Bruneck Study 1990–2010, n = 927)
Participants
without type 2
diabetes (n = 858)
Participants with
type 2 diabetes
(n = 69) P value
Arthroplasty
No. of cases 73 13
Person-years of follow-up 13,835 735
Intervention rate per 1,000
person-years 5.3 (4.1–6.6) 17.7 (9.4–30.2)
Cox models [HR (95% CI)]
Unadjusted 1 (Reference) 3.76 (2.07–6.81) ,0.001
Multivariable model 1a 1 (Reference) 2.06 (1.11–3.84) 0.023
Multivariable model 1a,b 1 (Reference) 2.20 (1.19–4.09) 0.013
Multivariable model 1a,c 1 (Reference) 1.72 (1.01–2.93) 0.045
Multivariable model 1a,d 1 (Reference) 2.19 (1.27–3.80) 0.005
Multivariable model 1a,e 1 (Reference) 1.81 (1.00–3.26) 0.049
Multivariable model 2f 1 (Reference) 2.08 (1.09–3.95) 0.026
Multivariable model 2f,g 1 (Reference) 2.09 (1.10–3.99) 0.025
HR and 95% CI were derived from Cox regression analysis. Participants with arthroplasty and those turning
90 years of age were censored for subsequent follow-up. aAdjusted for age, sex, prior joint replacement, BMI,
and loge-transformed level of soluble VCAM-1.
bIn this analysis, baseline BMIwas updated every 5 years (Cox
regression analysis with time-dependent covariate) to account for weight gain (e.g., related to insulin
treatment). cIn this analysis, baseline diabetes status was continuously updated during the 20-year follow-up
period (Cox regression analysis with time-dependent covariate). dIn this analysis, baseline diabetes status
was continuously updated during the first 10-year follow-up period (Cox regression analysis with time-
dependent covariate). This approach ensures adequate exposure time for severe OA to emerge and considers
the fact that the average time interval between diagnosis of diabetes and arthroplasty was .10 years in our
study. eIn this analysis, the most recent diagnostic criteria for type 2 diabetes of the American Diabetes As-
sociation were applied (see RESEARCH DESIGN AND METHODS; n = 93 at baseline). fAdjusted for everything in
footnote a and for social class, smoking, alcohol consumption, physical activity score, and levels of uric acid,
creatinine, LDL cholesterol, loge-transformed hsCRP, and ferritin.
gSix subjects with arthroplasty due to
severe OA prior to baseline (1990) were excluded.
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severe disease phenotype of OA, which is
less prevalent. Moreover, results from our
study launched in a small town, in which
accessibility to health resources is very
high, are not necessarily representative for
other Western populations and await con-
firmation in independent studies. Also, we
cannot exclude different decision-making
for arthroplasty in diabetic versus nondia-
betic subjects. Subjects with diabetes may
receive more medical attention than non-
diabetic individuals, leading to increased
awareness of or even overtreatment of
OA. Moreover, fear of deterioration of the
general medical condition in diabetic sub-
jects could, at least theoretically, lead to
earlier interventions in this group. In con-
trast, studies showing a higher risk of
complications and of revisions of arthro-
plasty in diabetic subjects could translate
into a more conservative indication for
surgical interventions resulting in an un-
derestimation rather than overestimation
of the effect size of diabetes in our study
(29). Actually, in the current study, radio-
graphic severity of OA prior to surgery
(Kellgren-Lawrence score) and the age at
arthroplasty both were identical in sub-
jects with and without type 2 diabetes,
suggesting no major differences in the
indication for interventions in these
groups.
The link between obesity and OA is
well-established and particularly sup-
ported by longitudinal data showing
that obesity entails a higher risk for de-
veloping severe OA (6). Traditionally, me-
chanical factors have been considered to
explain more rapid joint degeneration in
obese individuals. However, this concept
has been challenged by the link between
obesity and OA in non–weight-bearing
joints, suggesting that metabolic changes
directly enhance the risk of OA. Despite
evidence from cross-sectional studies that
OA is linked to the metabolic syndrome
and higher blood glucose levels (10–12),
no study addressed whether diabetes is in-
dependently linked to OA and in particular
whether such a link is independent of body
weight. Our study is the first to show that
type 2 diabetes predicts severe OA inde-
pendent of age, sex, and BMI and provides
both longitudinal and cross-sectional evi-
dence for an independent association be-
tween type 2 diabetes and OA.
Moreover, several lines of experimen-
tal evidence may help to explain the link
between type 2 diabetes and OA: 1) chon-
drocytes express the GLUT/SLC2A, and
high blood glucose levels shift the synthe-
sis pattern of chondrocytes from type II
collagen to reactive oxygen species, po-
tentially mediating cartilage destruction
(30–32). 2) Advanced glycosylation end
products elicited by sustained hyper-
glycemia can stimulate chondrocyte
expression of proinflammatory and pro-
degenerative proteins via the receptor for
advanced glycosylation end products
(33–35). In this context, it is worth men-
tioning that elevated circulating levels of
interleukin-6 and tumor necrosis factor-a
have recently been demonstrated in pa-
tients with knee OA (36). Moreover, our
data from knee US showed that signs of
inflammation are more frequent and se-
vere in the joints of diabetic subjects than
nondiabetic individuals. 3) Finally, sen-
sory and motor polyneuropathy is a com-
mon complication of type 2 diabetes and
may increase the risk of OA by muscle
weakness and loss of vibratory sense
(37) with subsequent inappropriate use
of the affected joint due to altered me-
chanical stress forces. In this context, it
is noteworthy that the pain subscales of
the WOMAC and KOOS scores exhibit
particularly pronounced associations
with type 2 diabetes (Table 2). Sensory
polyneuropathy obviously does not offset
the high burden of pain in OA among di-
abetic subjects, rendering this potential
link even more robust.
Our study fosters the concept that OA
is part of the metabolic syndrome. This
Figure 1dA: Disease duration of type 2 diabetes in diabetic patients with and without arthroplasty due to severe OA. B: Cumulative hazard curves
for total knee and hip arthroplasty (OA) by type 2 diabetes status, 1990–2010 (n = 927) (P = 0.023).
care.diabetesjournals.org DIABETES CARE, VOLUME 36, FEBRUARY 2013 407
Schett and Associates
notion shifts the traditional perception of
OA as a degenerative joint disease based
on continuous mechanical overload to a
metabolic etiopathogenesis. The link be-
tween OA and type 2 diabetes suggests
that alterations in glucose metabolism
directly affect joint integrity indepen-
dently of body weight and creates room
for hope that adequate control of glucose
metabolism hampers development of
OA. Our findings may thus add a novel,
modifiable, and highly prevalent risk
condition for the development of OA.
In summary, our data show that type
2 diabetes is a strong predictor for the
development of severe OA. This finding is
independent of age and BMI and suggests
that longstanding diabetes per se is detri-
mental for knee and hip joints, leading to
progressive destruction and joint failure.
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